In a small cohort of hospitalized, moderately to severely immunocompromised patients with COVID-19, ensitrelvir was associated with low 28-day mortality, with outcomes comparable to remdesivir. Larger prospective studies are needed. journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com